Xilio Therapeutics Announces 1-for-14 Reverse Stock Split
Rhea-AI Summary
Xilio Therapeutics (Nasdaq: XLO) will implement a 1-for-14 reverse stock split effective 5:00 p.m. ET on March 13, 2026, with split-adjusted trading beginning March 16, 2026 under ticker XLO and new CUSIP 98422T209. The split reduces outstanding shares from approximately 73.5 million to approximately 5.2 million.
The company said one primary goal is to increase its per-share market price to enable regaining compliance with Nasdaq Capital Market minimum bid price requirements. Warrants, equity awards and plan share pools will be proportionately adjusted; fractional shares will receive cash payments.
Positive
- Implemented a 1-for-14 reverse stock split to raise per-share market price
- Outstanding shares reduced from ~73.5 million to ~5.2 million
- Split-adjusted trading to begin March 16, 2026 under existing ticker XLO
- Proportionate adjustments to warrants, equity awards and plan share pools
Negative
- Company needed a reverse split to seek regaining Nasdaq minimum bid-price compliance
- Reverse split substantially reduces share count (~92.9% reduction from 73.5M to 5.2M)
- Holders entitled to fractional shares will receive cash instead of fractional stock
News Market Reaction – XLO
On the day this news was published, XLO declined 5.31%, reflecting a notable negative market reaction. Argus tracked a trough of -20.6% from its starting point during tracking. Our momentum scanner triggered 5 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $2M from the company's valuation, bringing the market cap to $40M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
XLO is down 3.57% while close biotech peers show mixed moves: MRSN up 0.62%, LVTX down 3.87%, BCAB down 6.87%, JSPR down 2.9%. With no peer momentum flags and no same-day peer news, the reverse split looks stock-specific rather than a sector-wide move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 02 | Conference participation | Neutral | +2.4% | Announcement of participation in Leerink Partners Global Healthcare Conference. |
| Mar 02 | Equity awards | Neutral | +2.4% | Inducement stock option grants to new employees under 2022 plan. |
| Feb 11 | Capital raise | Negative | +11.4% | Pricing of underwritten offering of pre-funded warrants for about $40M. |
| Jan 08 | Corporate update | Positive | +2.6% | Cash runway to Q2 2027 and masked IO pipeline and collaboration milestones. |
| Nov 13 | Earnings and pipeline | Positive | -9.3% | Q3 2025 results with positive clinical data and runway into Q1 2027. |
Recent news often produced moderate single-day moves, but the underwritten offering and earnings update both showed price reactions that diverged from their generally positive or supportive fundamentals.
Over the last few months, Xilio has balanced financial strengthening with pipeline progress. A January 2026 corporate update highlighted $137.5M cash and runway into Q2 2027, plus advancement of masked immuno-oncology programs. February’s underwritten offering of pre-funded warrants targeting about $40.0M in gross proceeds was followed by multiple Schedule 13G/A filings from major life sciences investors. More recently, inducement option grants and a Leerink conference appearance had modest positive price reactions. Today’s reverse split follows that capital-raising and listing-compliance backdrop.
Market Pulse Summary
The stock moved -5.3% in the session following this news. A negative reaction despite the mechanical nature of a reverse split would fit prior divergence patterns, such as the selloff after positive earnings on Nov 13, 2025. The move could reflect concerns about listing risk and prior dilutive financings, including the $40.0M pre-funded warrant offering. With shares already 54.24% below the $1.18 52-week high, any further weakness might have been influenced by sentiment rather than new fundamentals.
Key Terms
reverse stock split financial
nasdaq capital market regulatory
cusip financial
warrants financial
equity incentive plans financial
stock options financial
proxy statement regulatory
exchange agent financial
AI-generated analysis. Not financial advice.
WALTHAM, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced that it will implement a 1-for-14 reverse stock split of the issued shares of the company’s common stock, effective at 5:00 p.m. Eastern Time on March 13, 2026.
The reverse stock split was approved by the company’s stockholders at the company’s Special Meeting of Stockholders held on February 23, 2026, with the final ratio subsequently determined by the company’s Board of Directors. One of the primary goals of the reverse stock split is to increase the per-share market price of the company’s common stock to enable the company to regain compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market.
The company’s common stock is expected to begin trading on a split-adjusted basis when the markets open on March 16, 2026 under the company’s existing ticker “XLO” with the new CUSIP number 98422T209.
At the effective time of the reverse stock split, every 14 shares of the company’s issued and outstanding common stock will be automatically reclassified and combined into one share of common stock. This will reduce the number of outstanding shares of Xilio’s common stock from approximately 73.5 million shares to approximately 5.2 million shares. The reverse stock split will not change the number of authorized shares of the company’s common stock or the par value of the common stock. All outstanding warrants and other securities entitling their holders to purchase or otherwise receive shares of common stock will be adjusted as a result of the reverse split, as required by the terms of each security. In addition, proportionate adjustments will be made to the number of shares of common stock available for issuance under the company's equity incentive plans and the number of shares underlying and, in the case of stock options, the exercise prices of, outstanding equity awards under such plans, in accordance with their respective terms and as described in the company's proxy statement for its Special Meeting of Stockholders as filed with the Securities and Exchange Commission (SEC) on January 26, 2026 (the Proxy Statement).
No fractional shares will be issued if, as a result of the reverse stock split, a stockholder would otherwise become entitled to a fractional share because the number of shares of common stock they hold before the reverse stock split is not evenly divisible by the split ratio. Instead, each such stockholder will be entitled to receive a cash payment in lieu of a fractional share.
Computershare Trust Company, N.A. is acting as the exchange agent and transfer agent for the reverse stock split. Stockholders holding their shares electronically are not required to take any action to receive post-split shares. Stockholders owning shares through a bank, broker or other nominee will have their positions adjusted to reflect the reverse stock split and will receive payment for any fractional shares in accordance with the processes at their respective bank, broker or nominee. Additional information regarding the reverse stock split can be found in the Proxy Statement.
About Xilio Therapeutics
Xilio Therapeutics is a clinical-stage biotechnology company discovering and developing masked immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is leveraging its proprietary masking technology to advance a pipeline of novel, masked I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment. Learn more by visiting www.xiliotx.com and follow us on LinkedIn (Xilio Therapeutics, Inc.).
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding the reverse stock split and the timing thereof, the impact of the reverse stock split on stockholders and other securityholders; and the potential for Xilio to increase its share price and regain compliance with the Nasdaq continued listing rules. The words “aim,” “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “seek,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of important risks, uncertainties and other factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, risks related to general market conditions and geopolitical uncertainties; risks and uncertainties related to ongoing and planned research and development activities, including initiating, conducting or completing preclinical studies and clinical trials and the timing and results of such preclinical studies or clinical trials; the delay of any current or planned preclinical studies or clinical trials or the development of Xilio’s current or future product candidates; Xilio’s need to obtain additional cash resources to advance its pipeline of tumor-activated I-O molecules; the impact of international trade policies on Xilio’s business, including U.S. and China trade policies; and Xilio’s ability to maintain its collaboration or partnership agreements with AbbVie, Gilead and Roche. These and other risks and uncertainties are described in greater detail in the sections entitled “Risk Factor Summary” and “Risk Factors” in Xilio’s filings with the SEC, including Xilio’s most recent Quarterly Report on Form 10-Q and any other filings that Xilio has made or may make with the SEC in the future. Any forward-looking statements contained in this press release represent Xilio’s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Except as required by law, Xilio explicitly disclaims any obligation to update any forward-looking statements.
This press release contains hyperlinks to information that is not deemed to be incorporated by reference in this press release.
Investor Contact
Alex Lobo, Precision AQ
alex.lobo@precisionaq.com
Media Contact
Josie Butler, 1AB
josie@1abmedia.com
FAQ
When does Xilio (XLO) reverse stock split take effect and when will shares trade post-split?
What is the reverse split ratio for Xilio (XLO) and how will it change outstanding shares?
Why is Xilio (XLO) doing a 1-for-14 reverse stock split on March 13, 2026?
How will Xilio (XLO) handle fractional shares after the reverse stock split?
What happens to Xilio (XLO) warrants, stock options, and equity plan shares after the reverse split?
